Kissei Pharmaceutical Co., Ltd. (TYO:4547)
4,185.00
+60.00 (1.45%)
Jul 16, 2025, 3:30 PM JST
Kissei Pharmaceutical Balance Sheet
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Cash & Equivalents | 25,169 | 22,894 | 25,893 | 30,013 | 20,456 | Upgrade |
Short-Term Investments | 23,485 | 23,039 | 23,706 | 23,139 | 23,998 | Upgrade |
Cash & Short-Term Investments | 48,654 | 45,933 | 49,599 | 53,152 | 44,454 | Upgrade |
Cash Growth | 5.92% | -7.39% | -6.69% | 19.57% | -25.50% | Upgrade |
Receivables | 28,951 | 27,790 | 22,083 | 21,956 | 23,058 | Upgrade |
Inventory | 24,979 | 26,296 | 22,798 | 18,987 | 20,118 | Upgrade |
Other Current Assets | 4,396 | 4,532 | 6,161 | 5,247 | 5,335 | Upgrade |
Total Current Assets | 106,980 | 104,551 | 100,641 | 99,342 | 92,965 | Upgrade |
Property, Plant & Equipment | 27,069 | 24,861 | 24,579 | 24,074 | 24,290 | Upgrade |
Long-Term Investments | 107,544 | 128,910 | 94,034 | 112,574 | 149,365 | Upgrade |
Goodwill | 242 | 309 | - | - | - | Upgrade |
Other Intangible Assets | 1,652 | 1,683 | 1,507 | 1,569 | 1,640 | Upgrade |
Long-Term Deferred Tax Assets | 566 | 608 | 433 | 524 | 585 | Upgrade |
Other Long-Term Assets | 1 | 2 | 1 | 1 | 2 | Upgrade |
Total Assets | 244,059 | 260,929 | 221,200 | 238,087 | 268,861 | Upgrade |
Accounts Payable | 4,602 | 4,893 | 4,617 | 4,104 | 7,909 | Upgrade |
Accrued Expenses | 2,192 | 1,856 | 1,679 | 1,721 | 1,830 | Upgrade |
Short-Term Debt | 1,280 | 1,340 | 1,490 | 1,640 | 1,743 | Upgrade |
Current Income Taxes Payable | 1,474 | 2,380 | 408 | 3,497 | 1,487 | Upgrade |
Other Current Liabilities | 7,030 | 7,194 | 6,763 | 7,782 | 5,276 | Upgrade |
Total Current Liabilities | 16,578 | 17,663 | 14,957 | 18,744 | 18,245 | Upgrade |
Long-Term Deferred Tax Liabilities | 16,481 | 21,188 | 10,426 | 16,259 | 28,480 | Upgrade |
Other Long-Term Liabilities | 673 | 735 | 812 | 724 | 786 | Upgrade |
Total Liabilities | 33,934 | 39,795 | 26,387 | 35,908 | 48,909 | Upgrade |
Common Stock | 24,356 | 24,356 | 24,356 | 24,356 | 24,356 | Upgrade |
Additional Paid-In Capital | 24,226 | 24,226 | 24,226 | 24,226 | 24,226 | Upgrade |
Retained Earnings | 131,488 | 127,310 | 125,576 | 118,183 | 109,270 | Upgrade |
Treasury Stock | -14,520 | -13,209 | -12,912 | -12,912 | -12,911 | Upgrade |
Comprehensive Income & Other | 43,453 | 57,344 | 32,653 | 47,532 | 74,373 | Upgrade |
Total Common Equity | 209,003 | 220,027 | 193,899 | 201,385 | 219,314 | Upgrade |
Minority Interest | 1,122 | 1,107 | 914 | 794 | 638 | Upgrade |
Shareholders' Equity | 210,125 | 221,134 | 194,813 | 202,179 | 219,952 | Upgrade |
Total Liabilities & Equity | 244,059 | 260,929 | 221,200 | 238,087 | 268,861 | Upgrade |
Total Debt | 1,280 | 1,340 | 1,490 | 1,640 | 1,743 | Upgrade |
Net Cash (Debt) | 47,374 | 44,593 | 48,109 | 51,512 | 42,711 | Upgrade |
Net Cash Growth | 6.24% | -7.31% | -6.61% | 20.61% | -26.25% | Upgrade |
Net Cash Per Share | 1086.01 | 985.30 | 1043.24 | 1117.03 | 915.25 | Upgrade |
Filing Date Shares Outstanding | 41.44 | 44.21 | 45.96 | 46.12 | 46.12 | Upgrade |
Total Common Shares Outstanding | 42.81 | 44.21 | 46.12 | 46.12 | 46.12 | Upgrade |
Working Capital | 90,402 | 86,888 | 85,684 | 80,598 | 74,720 | Upgrade |
Book Value Per Share | 4882.67 | 4977.38 | 4204.63 | 4366.94 | 4755.71 | Upgrade |
Tangible Book Value | 207,109 | 218,035 | 192,392 | 199,816 | 217,674 | Upgrade |
Tangible Book Value Per Share | 4838.42 | 4932.32 | 4171.95 | 4332.92 | 4720.15 | Upgrade |
Order Backlog | 3,403 | 2,613 | 2,098 | 1,479 | 2,726 | Upgrade |
Updated Feb 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.